3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
52
Breast Neoplasms
24
Lung Neoplasms
21
Triple Negative Breast Neoplasms
16
Neoplasm Metastasis
16
Pancreatic Neoplasms
15
Neoplasms
15
Colorectal Neoplasms
14
Stomach Neoplasms
13
Head and Neck Neoplasms
12
Esophageal Neoplasms
12
Esophageal Squamous Cell Carcinoma
11
Uterine Cervical Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Small Cell Lung Carcinoma
9
Rectal Neoplasms
8
Ovarian Neoplasms
8
Leukemia, Myeloid, Acute
8
Recurrence
7
Nasopharyngeal Carcinoma
7
Glioblastoma
5
Fallopian Tube Neoplasms
5
Cholangiocarcinoma
5
Urinary Bladder Neoplasms
4
Sarcoma
4
Oropharyngeal Neoplasms
4
Mouth Neoplasms
4
Lymphoma
4
Endometrial Neoplasms
4
Colonic Neoplasms
4
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Drug Therapy
×
1 year
×
Clear all
NCT06504615
2026-04-03
METAGIO
Bristol-Myers Squibb
Active not recruiting
208 enrolled